Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions... Show more
Axon Enterprise, the public-safety technology company behind TASER devices, body cameras, and cloud software, has become one of the market's most consistent high-growth names. Its AI Era Plan, counter-drone (Dedrone) business, and premium software offerings have driven double-digit growth across nearly every product line. Yet the stock has lagged its own fundamentals in 2026, as software-sector weakness and questions about hardware margins weigh on sentiment. This upcoming report matters because it will show whether Axon can sustain its expansion while defending profitability, a balance that has become the central debate for investors heading into the print.
Analysts expect Axon to report third-quarter 2026 non-GAAP EPS of approximately $1.94, a jump from $1.17 in the year-ago quarter, on revenue of about $940 million, up from $710.6 million a year earlier. Consensus figures cluster tightly, with most estimates ranging from about $1.93 to $1.94 in EPS and $940 million to $943 million in revenue.
For context, Axon posted second-quarter 2026 revenue of $904.3 million, up 35% year over year and ahead of estimates, with non-GAAP EPS of $1.88. The company has beaten EPS estimates in seven of its last eight quarters, giving it a strong track record of outperformance.
Management has raised its full-year 2026 revenue growth outlook to 32%–34% and maintained an adjusted EBITDA margin target of approximately 25.5%. Investors will watch the third-quarter figures for confirmation that this guidance remains intact, particularly given rising component costs. Key metrics beyond the headline numbers include adjusted gross margin, annual recurring revenue (ARR) of roughly $1.6 billion, and future contracted bookings, which surpassed $15 billion last quarter.
Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring names like Axon ahead of earnings, tools of this kind offer a faster way to surface relevant setups and compare opportunities across industries.
Sentiment heading into this report is cautious despite Axon's operational strength. After its second-quarter beat in August, shares fell roughly 6.5% in after-hours trading, as investors focused on anticipated margin pressure in the third quarter from memory costs and the absence of a tariff refund benefit. The stock has continued to slide since then, trading well below its 52-week high, and has been further pressured by a $1 billion convertible note offering announced in September. Analysts remain broadly constructive, with a consensus "Buy" rating and an average price target well above current levels, but the market's focus has shifted from growth alone to the quality of that growth, making this quarter's margin commentary a key swing factor for sentiment.
Beyond the headline numbers, investors should focus on several signals that will shape the narrative after this report.
First, adjusted gross margin is critical. Tariffs, higher memory costs, and a mix shift toward hardware have compressed margins in recent quarters. Commentary on whether these pressures are easing or persisting will matter more to the stock than a modest revenue beat.
Second, watch the trajectory of recurring revenue and bookings. Axon's ARR and future contracted bookings provide visibility into future demand, and sustained growth here would reinforce confidence in the company's long-term expansion across software and services.
Third, monitor the pace of AI and counter-drone adoption. The AI Era Plan and Dedrone platform have been standout growth drivers, and any sign of deceleration would be closely scrutinized given how much of the growth narrative depends on them.
Finally, investors will look for any update to full-year guidance. Management's current outlook of 32%–34% revenue growth and a roughly 25.5% adjusted EBITDA margin sets a clear bar, and how executives frame the fourth quarter, which is historically the company's strongest, will influence expectations for the balance of the year.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a clinical-stage biopharmaceutical company
Industry AerospaceDefense